Inhibition LC3B can increase chemosensitivity of ovarian cancer cells release_lscsk7gwbnhppirgdu7eon6vey

by Jing Tang, Jiang Zhu, Yuguang Ye, Yu Liu, Yan He, Lei Zhang, Dai Tang, Cong Qiao, Xinxin Feng, Junyi Li, Yanni Kan, Xiaobo Li (+2 others)

Published in Cancer Cell International by Springer Science and Business Media LLC.

2019   Volume 19, p199

Abstract

Ovarian cancer is often accompanied by the production of ascites, and patients with repeated ascites are associated with chemotherapy resistance. The previous study confirmed that the ovarian cancer patients who developed ascites after chemotherapy had elevated autophagy levels in the ascites and precipitated cells, which was positively correlated with MDR1 expression in the blood of patients. In order to explore the correlation between autophagy and chemoresistant, we searched TCGA and GEO database to analyze the correlation between LC3B and MDR1, and identified the targeting miRNA of LC3B. It was verified by dual luciferase that miR-204 can target LC3B. The ovarian cancer cell line and the BALB/c nude mice tumor-bearing model were selected for in vitro and in vivo verification. In vitro studies confirmed that ovarian cancer cells were more sensitive to cisplatin by inhibiting LC3B. Overexpression of miR-204 reduced the expression of LC3B, Atg7, and MDR1, and promoted apoptosis. In vivo studies have also confirmed that reducing the level of autophagy in ovarian cancer cells increases the sensitivity to cisplatin. It suggests that miR-204 can be used as a tumor suppressor gene and LC3B expression level can be used as a potential molecular marker to guide the diagnosis and treatment of patients with ovarian cancer.
In text/plain format

Archived Files and Locations

application/pdf  7.4 MB
file_63koc4ilmncmxfwz5ww3iphvui
web.archive.org (webarchive)
cancerci.biomedcentral.com (publisher)
Read Archived PDF
Archived
Type  article-journal
Stage   published
Date   2019-07-29
Language   en ?
Container Metadata
Open Access Publication
In DOAJ
In ISSN ROAD
In Keepers Registery
ISSN-L:  1475-2867
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: cf657ce4-9945-4414-bc32-535270840265
API URL: JSON